The Evaiuation of chalator therapy in reducing serum ferritin and improving Ejection fraction (EF%) in thalassemic patients

Thalassemic syndroms are the most common genetic disease in the world that related to blood transfusion and iron overload in the body. Cardiac complications are the leading cause of death in patients with thalassemia. Cardiovascular complications in patients largely decreases with iron chelators medications. In this study effect, complications and acceptance of iron chelator therapy was evaluated in thalassemic patients. In this prospective study (cohort), all treated patients in thalassemia centers in Bushehr were divided into 5 groups based on their use of the drug chelators include: Deferral, Asvral, deferiprone, Exjad, Deferral+deferiprone. Serum ferritin levels at baseline and 6 months after treatment and the percentage of EF with echocardiography at baseline and after 2±8 months were measured. Symptoms were assessed by interview and physical examination. Data were analyzed with SPSS statistical software by using appropriate statistical tests. Ferritin levels decreased in all groups except deferiprone group (from 1853 mg% to 2356 mg P=0.01).EF% was developed in all groups but was significant in defroperone group (from 62% to 71%, P=0.027).The highest incidence complication was in desferal +defrepiron group. 93.3% of patients were satisfied with their medication. Deferiprone had better effect in reducing cardiac hemocidrosis and improving cardiac function.Desferal more effective in reducing serume ferritin. Deferiprone improved heart function with better effect in reducing heart hemoicidrosis. Iron chelators are effective in reducing complications and mortality rate in thalassemic patients. Defrepirone had particular special effect on improving of the heart function. patients can use from these drugs are by support by insurance organization.